Sildenafil

Intro

Sildenafil citrate was developed in 1989 at Pfizer's Sandwich, UK laboratories by Drs. Peter Dunn and Albert Wood, targeting angina via prolonged cGMP signaling.

Phase I trials in 1991 showed insufficient antihypertensive effect, but the study's male participants were reluctant to return their remaining tablets — they reported consistent drug-associated erections. This serendipitous observation redirected the entire development program.

The FDA approved sildenafil on March 27, 1998 as Viagra — the first oral ED treatment. Within 6 months, 5.3 million prescriptions had been written. The discovery was enabled by Nobel Prize-winning work from Furchgott, Ignarro, and Murad on nitric oxide's role in the cardiovascular system; sildenafil is the direct pharmacological application of their discovery.

A second indication emerged from the same mechanism. PDE5 is expressed in pulmonary vasculature, not just penile tissue. Sildenafil was approved as Revatio (20mg three times daily) for pulmonary arterial hypertension in 2005 — a chronic use pattern at a fraction of the ED dose. This approval validated the compound's vascular biology beyond erectile function.

The bodybuilding community adopted sildenafil in the early 2000s after early adopters realized that PDE5 inhibition enhances blood flow to working muscle tissue just as it does to erectile tissue. Generic sildenafil became available in the US in 2017 after patent expiry, driving the price from $30+ per pill to under $2. This cost collapse accelerated community adoption substantially. Today sildenafil is used for four distinct purposes: ED management (the primary indication), pre-workout pump enhancement, PAH treatment, and off-label altitude sickness prophylaxis.

Observed Effects

Erectile dysfunction efficacy: Across 27 RCTs (6,659 men), sildenafil produced successful intercourse in 57% of attempts vs 21% on placebo — a 33.7% weighted mean difference.

83% of men experienced at least one successful intercourse during treatment vs 45% on placebo. Efficacy was maintained across all evaluated subgroups: diabetic men (response rates somewhat lower but still significant), spinal cord injury, psychogenic ED, and men on antihypertensive or antidepressant medications. One-year efficacy was maintained without tolerance development.

Pump and vasodilation: In healthy users, sildenafil 25–50mg enhances skeletal muscle blood flow during training via the same NO/cGMP mechanism that operates in erectile tissue. The effect is real and community-validated: increased pump, improved vascularity, enhanced nutrient delivery. A small RCT (n=11, 15 days, 25mg/day) found sildenafil nearly doubled skeletal muscle protein synthesis vs placebo and reduced muscle fatigue — an intriguing finding that needs replication.

Pulmonary and cardiovascular effects: Sildenafil significantly reduces mean pulmonary arterial pressure and systolic pulmonary arterial pressure in PAH patients, with improved exercise capacity. Blood pressure in healthy subjects falls modestly (~4–8 mmHg systolic). Long-term use has been associated with improved endothelial function, reduced CRP and inflammatory markers, and mild increases in testosterone/DHT (proposed mechanism: improved testicular blood flow via better vasodilation).

SSRI-induced sexual dysfunction: Effective at 50mg on-demand for ED caused by SSRIs — addresses the NO/cGMP component of SSRI-induced dysfunction even when other components (prolactin, dopamine) are involved.

Athletic performance: Despite investigation for WADA's prohibited list, controlled studies in healthy trained athletes show lackluster endurance or strength improvements. The pump benefit is acute and local, not a systemic performance-enhancing effect.

Field Reports

What works At 25mg pre-workout, virtually all users notice enhanced pump and vascularity relative to training without sildenafil.

The effect is consistent and dose-reliable — there's no 'it worked last time, why not today?' variability that plagues some compounds. For ED use, the community reports essentially identical experience to the clinical data: very high response rate, predictable onset, reliable duration.

Tolerance does not appear to develop meaningfully for ED users — men report consistent response at the same dose after years of use. Where apparent 'tolerance' occurs, the underlying cause is usually disease progression (worsening vasculopathy) rather than pharmacological tolerance.

What doesn't work Sildenafil after a large meal is the most common user failure. High-fat meals delay onset by ~1h and reduce peak levels by ~29%. Users who take sildenafil at the dinner table expecting results by 10pm after a 7pm steak dinner are frequently disappointed. The fix is simple: take on empty stomach or at least 2h post-meal.

Sildenafil at 100mg for gym use is usually counterproductive. The blood pressure reduction becomes symptomatic during heavy compound movements (squats, deadlifts) that require venous return. Lightheadedness is common at this dose during intense training. 25mg is the correct gym dose.

The 'extreme pump' failure mode: stacking sildenafil + high-dose citrulline + high-rep training can produce a pump so severe that range of motion is compromised — the muscle pump forces partial reps. Moderation is required.

Common mistakes Combining sildenafil with a stimulant-based pre-workout. Caffeine/ephedrine cause sympathetic vasoconstriction that partially counteracts sildenafil's vasodilation — the result is a blunted pump and potentially unpredictable BP. Use stimulant-free citrulline supplements (Gorilla Mode Nitric or equivalent) when stacking with sildenafil.

Using sildenafil without checking for concurrent medications. Men taking prazosin (alpha-blocker) for blood pressure, or who've been prescribed nitroglycerin PRN for cardiac symptoms, need to disclose this before starting. The nitrate interaction is the most critical drug safety fact in all of PDE5i pharmacology.

Protocol refinements from experienced users Start with 12.5mg for the first gym session and assess blood pressure response before titrating to 25mg. Rotate between sildenafil (for planned high-intensity pump sessions) and tadalafil daily 5mg (for background coverage and spontaneous situations). Build flushing tolerance by starting at low doses and titrating up over 2–3 weeks. If experiencing visual effects at 100mg, drop to 50mg — the PDE6 effect is dose-dependent.

Community Consensus

Sildenafil entered medical practice in 1998 and the fitness community shortly after. The initial adoption was driven by early bodybuilders and TRT users who discovered that PDE5 inhibition enhanced workout pump in the same way it enhanced penile blood flow — the same vascular biology operates in both tissues.

The community split between sildenafil and tadalafil is primarily pharmacokinetic. Sildenafil is the on-demand precision tool used shortly before the gym or bedroom session for 4-6h of enhanced vasodilation. Tadalafil is the background infrastructure compound: daily low-dose use maintains a steadier baseline. Most advanced community members use one or the other based on their use case — sildenafil for specific pre-workout sessions or planned sexual encounters, tadalafil daily for men who want continuous coverage.

The gym use case is well-established but somewhat overhyped. Sildenafil produces a real, visible improvement in pump and vascularity during training. The 2013 RCT showing near-doubled muscle protein synthesis at 25mg daily for 15 days is an intriguing but underpowered finding that the community has latched onto; it needs replication before being taken as a primary reason to use sildenafil for bodybuilding. The pump benefit is real. The hypertrophic benefit is speculative at this stage.

In TRT communities, some clinic protocols include occasional sildenafil alongside TRT for combined sexual function and blood pressure management benefits. This reflects the growing recognition that sildenafil is not just an ED drug but a mild vasodilator with documented endothelial benefits.

A conservative minority in the community pushes back on gym use: 'these should be used only in emergency situations, not treated like some sort of candy.' This view is in the minority; the mainstream community treats 25mg pre-workout as low-burden for healthy users without cardiovascular risk factors, while still treating nitrates, alpha-blockers, and unstable cardiac disease as serious exclusions.

Generic access transformed adoption. Once regulated generic sildenafil became inexpensive, the compound moved from a narrowly medical ED drug into a common vascular-support and pump-enhancement tool. That wider use also made dose confidence and product quality more important, because unregulated products can turn a familiar drug into a measurement and identity problem.

Risks & Monitoring

Sildenafil's adverse effect profile follows a dose-response spectrum driven by two mechanisms: vasodilation (dose-dependent across all tissues) and PDE6 cross-reactivity (dose-dependent, retinal-specific).

Vasodilation-related spectrum (25–100mg): Flushing (12%), headache (11%), nasal congestion, and dyspepsia (5%) are all direct consequences of systemic vasodilation. These increase with dose — RR=1.56 (95% CI 1.38–1.76) for all-cause adverse events vs placebo across 49 RCTs. All are mild, transient, and resolve as the drug clears. Flushing is the most subjectively noticeable: capillary dilation causes facial warmth described as 'face in a hot oven' by community users. Tolerance to flushing typically develops within 2–3 weeks of regular use.

Blood pressure effects: Sildenafil causes a transient 4–8 mmHg systolic BP reduction in normotensive users. This is clinically insignificant in isolation. It becomes dangerous when combined with: nitrates (absolute contraindication — severe hypotension with no safe dose), alpha-blockers (additive hypotension — start at 25mg, avoid within 4h of alpha-blocker), ARBs/ACE inhibitors + high-dose citrulline pre-workout (triple vasodilator stack — meaningful additive hypotension risk). Symptoms of overdose: lightheadedness, especially during heavy compound movements requiring venous return.

PDE6 cross-reactivity (visual disturbances): Sildenafil is 10-fold selective over retinal PDE6 — the weakest selectivity in its class (PDE1-4 selectivity is 80–19,000-fold). At 25–50mg, visual disturbances occur in ~3% of users. At 100mg, they're more common. Character: blue-green tinge to vision, increased light sensitivity. Fully reversible within hours. Avanafil (a newer PDE5i) has better PDE6 selectivity and fewer visual effects.

NAION (non-arteritic anterior ischemic optic neuropathy): Rare but serious. Risk is higher in men with pre-existing optic disc anatomic anomaly ('disc at risk'), diabetes, hypertension, or cardiovascular disease. If sudden vision loss occurs, discontinue immediately.

Melanoma risk: An umbrella review of 77 meta-analyses identified increased melanoma risk associated with sildenafil use. The mechanism is not established. Long-term users should maintain routine skin surveillance.

Priapism: Rare. Erection lasting >4h requires medical attention — aspiration or alpha-agonist injection. Risk increased with high doses, combination with other PDE5 inhibitors, or use with PT-141 or apomorphine.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Erectile dysfunction Start at 50mg on-demand. Take 45–60 minutes before activity on an empty stomach.

Titrate to 100mg if response is inadequate after 4–6 attempts, or down to 25mg for tolerability. If baseline testosterone is low, evaluate and treat hypogonadism — testosterone normalization often partially or fully resolves ED; sildenafil + testosterone replacement outperforms either alone in hypogonadal men. For SSRI-induced ED, 50mg on-demand is effective.

Gym pump enhancement 25mg taken 30–45 minutes pre-workout on an empty stomach. Stack with stimulant-free L-citrulline pre-workout (Gorilla Mode Nitric or equivalent) for additive effect — citrulline builds NO, sildenafil preserves cGMP. Avoid combining with stimulant-based pre-workouts (caffeine raises BP while sildenafil lowers it — opposing hemodynamic effects). If on ARB or other anti-hypertensive, cap sildenafil at 12.5–25mg and monitor BP. For anyone on an alpha-blocker: avoid sildenafil for pump use entirely unless medically supervised.

Daily background vasodilation (TRT users / longevity focus) Tadalafil 5mg daily is the preferred option for continuous coverage. If using sildenafil daily instead: 25mg on waking provides ~4–6h of coverage relevant to morning training sessions. Weekly 1–2 pill sildenafil use (alongside TRT) is an increasingly common TRT clinic prescribing pattern in the UK for combined ED management and mild BP reduction.

Pulmonary arterial hypertension Revatio 20mg three times daily (every 8 hours). This is a chronic medical treatment — not a self-administered fitness protocol. Requires physician supervision.

Altitude sickness prophylaxis 50mg every 8 hours beginning 24h before high-altitude ascent. Continue during the ascent phase. Tadalafil 10mg daily is an alternative with easier dosing due to longer half-life.

Dosing Details

Standard ED dosing: The labeled ED pattern is 50mg taken 30-60 minutes before sexual activity on an empty stomach or after a light meal, with 25-100mg as the usual adjustment range and no more than once-daily use.

Dose changes are normally based on response and side-effect tolerance.

Reduced-dose populations: Labeling and clinical practice use lower starting doses in older users, hepatic impairment, severe renal impairment (CrCl <30 mL/min), or concurrent CYP3A4 inhibitors (ritonavir, ketoconazole, erythromycin, itraconazole, cimetidine). With ritonavir specifically, the labeled ceiling is 25mg per 48h, not once daily.

Timing: Onset typically 30-60 minutes fasted; up to 2 hours if taken with a high-fat meal. The peak effect window is the first 1-2h after onset; the tail of the 4-6h duration window has progressively weaker effect.

Pre-workout pump use: 25mg is the community-established pump dose — sufficient for meaningful vasodilation without the blood pressure drop that becomes problematic during heavy compound movements at 50-100mg. Some users report 12.5mg as a conservative first exposure. Liquid forms add concentration and measurement uncertainty.

Daily low-dose: Less common for sildenafil due to the 4h half-life (compared to tadalafil 5mg daily which maintains steady state). Some users report 25mg daily for morning workouts, accepting that the effect windows do not provide continuous coverage. Tadalafil 5mg daily is generally preferred for any continuous-coverage protocol.

PAH dosing (Revatio): 20mg three times daily, every 8 hours. This regimen maintains trough plasma levels for continuous pulmonary vascular pressure reduction. This is an entirely different use pattern from on-demand ED dosing.

Altitude sickness (off-label): 50mg every 8 hours beginning 24 hours before ascent is described in off-label contexts. Tadalafil is also used for this purpose.

Forms: Tablet (25mg, 50mg, 100mg — brand and generic). Liquid and oral disintegrating formats exist in some markets, but the article's cleanest dose assumptions come from regulated tablets. No injection form.

Stacks & Alternatives

Synergistic with sildenafil for pump. L-citrulline → arginine → eNOS → NO → cGMP. Sildenafil then prevents cGMP breakdown. Addressing both sides of the cGMP equation (production and degradation) gives a compounded pump effect. Use stimulant-free citrulline pre-workout to avoid opposing hemodynamic effects.

Natural mild PDE inhibitors and endothelial support supplements. Hawthorn berry 250–500mg + grape seed extract 100–200mg complement sildenafil's mechanism. Add these to the citrulline-sildenafil stack for a more complete NO/cGMP optimization protocol.

Testosterone + sildenafil combination is superior to either alone in hypogonadal men with ED. Testosterone normalizes the hormonal environment that determines baseline NO production and erectile response. TRT clinics increasingly prescribe sildenafil 1–2x/week alongside TRT for combined ED management and mild blood pressure reduction.

Apomorphine acts centrally via dopamine D2/D4 receptors to drive the psychogenic component of erection; sildenafil acts peripherally via PDE5 inhibition. The combination addresses both central and peripheral components of ED in men who are partial non-responders to sildenafil alone.

Omega-3 supplementation improves endothelial function and reduces inflammatory markers. Better endothelium = better NO release = better sildenafil response. Hans Mato recommends 3g EPA + 2g DHA daily as a foundational stack component for PDE5 inhibitor optimization.

Alternatives

Stack Cost

Practical Setup

Product quality: Regulated tablets have the cleanest identity and dose assumptions. Unregulated liquids or international products add concentration, suspension, and labeling uncertainty; apparent non-response or excessive side effects can be a product-quality issue rather than a sildenafil issue.

Storage: Tablet form is stable at room temperature and should be protected from moisture. Liquid products are more variable and can separate, which adds another dose-consistency problem.

Drug interactions requiring dose adjustment: - Ritonavir: max 25mg per 48h - Ketoconazole/itraconazole: lower starting dose - Erythromycin: lower starting dose - Cimetidine: reduced starting dose - Grapefruit: avoid on the day of use - Alpha-blockers: lower starting dose and avoid close timing with alpha-blocker dose

Who should not take sildenafil without physician clearance: Men currently taking any nitrate for cardiac conditions. Men with recent MI, stroke, or unstable angina. Men with severe hypotension (BP <90/50) or uncontrolled hypertension (>170/100). Men with severe hepatic impairment.

When protocols are adjusted in reports: Consistent lightheadedness during training usually leads users to reduce the dose. Lack of response at a standard ED dose after multiple properly timed attempts should also prompt evaluation for low testosterone, vascular disease, medication interactions, or product-quality problems rather than automatic escalation. Visual disturbances are dose-dependent and often lead to dose reduction or switching to a more PDE6-selective alternative.

Hematocrit/TRT interaction: Men on TRT with elevated hematocrit (>50%) have increased blood viscosity and often elevated BP. Adding sildenafil can help normalize BP in this context, but the baseline BP context matters — monitor BP before adding sildenafil to a TRT protocol.

Overdose management: Sildenafil overdose produces excessive vasodilation and hypotension. Mild cases are typically managed with recumbency, fluids/electrolytes, and avoiding sudden standing while the drug clears. Severe symptoms such as syncope or chest pain require medical attention.

Mechanism Deep Dive

Nitric oxide / cGMP pathway During sexual stimulation (or exercise-induced vasodilation), parasympathetic nerves and vascular endothelium release nitric oxide (NO).

NO diffuses into smooth muscle cells and activates soluble guanylyl cyclase, converting GTP to cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain phosphatase and other targets, causing smooth muscle cell relaxation. In corpus cavernosum smooth muscle, this relaxation dilates the trabecular sinusoids, allowing arterial blood to fill the corpora and produce an erection. In skeletal muscle vasculature and pulmonary artery smooth muscle, the same sequence dilates arterioles and increases tissue perfusion.

Phosphodiesterase type 5 (PDE5) is the enzyme responsible for degrading cGMP — terminating the smooth muscle relaxation signal. Sildenafil binds competitively to the catalytic site of PDE5 with an IC50 of 3.5 nM, blocking cGMP hydrolysis and allowing cGMP to accumulate and persist.

Critical mechanistic constraint: sildenafil is a potentiator, not an initiator In the complete absence of NO drive, sildenafil has no effect on corpus cavernosum smooth muscle. This was confirmed in isolated human and rabbit tissue: sildenafil alone produces no relaxation; it only potentiates the effect of exogenous NO. This explains why sexual stimulation is required — the neurally-released NO provides the cGMP that sildenafil then protects from degradation. Without the NO signal, there is nothing to potentiate.

PDE5 selectivity profile Sildenafil is 80 to 19,000-fold selective over PDE1 through PDE4. Its weakest selectivity is over PDE6 — only 10-fold selective. PDE6 is concentrated in retinal rod and cone photoreceptors, where it participates in the phototransduction cascade (light response). This 10-fold selectivity margin is the direct mechanistic basis for sildenafil's visual side effects. At higher plasma concentrations (typically ~100mg dose), PDE6 inhibition in the retina alters the kinetics of the light response: patients report a blue-green tinge and increased light sensitivity. In the anesthetized dog, sildenafil modifies the a- and b-waves of the electroretinogram at concentrations ~30-fold higher than those active on intracavernosal pressure; in humans the ratio is closer and the effect appears at therapeutic doses in some users.

Cardiac selectivity Unlike PDE3 inhibitors (e.g., milrinone), sildenafil does not increase cardiac contractility. PDE5 selectivity over PDE3 (which regulates cAMP in cardiac muscle) means sildenafil lacks the inotropic and potentially arrhythmogenic effects associated with PDE3 inhibition. This is why sildenafil does not directly harm cardiac contractile function — though systemic vasodilation and BP reduction still stress the heart indirectly in compromised cardiovascular disease.

Pharmacokinetics Oral bioavailability: 41% (90% CI: 36–47%) — first-pass CYP3A4 (primary) and CYP2C9 (minor) hepatic metabolism accounts for the ~59% that doesn't reach systemic circulation. Tmax: 30–120 minutes (median ~1h fasted). High-fat meal: shifts Tmax +1h, reduces Cmax by 29% (90% CI: 19–38%), AUC reduced by only 11%. Elimination half-life: 3–5 hours. Active metabolite UK-103,320 (N-desmethyl-sildenafil) contributes ~20% of pharmacological activity and extends the effective duration slightly beyond the parent compound's half-life. Dose-AUC relationship is slightly supralinear (2.1-fold AUC increase per doubling of dose) — minimal saturation of first-pass metabolism at higher doses. The nitrate contraindication mechanism: nitrates spontaneously release NO → elevate cGMP; sildenafil blocks cGMP breakdown → extreme, cumulative vasodilation → severe hypotension.

Evidence Index